trending Market Intelligence /marketintelligence/en/news-insights/trending/qpow6kwh6x-gaxp8u5egvg2 content esgSubNav
In This List

Amgen closes tender offer for common shares

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amgen closes tender offer for common shares

Thousand Oaks, Calif.-based Amgen Inc. completed its tender offer to purchase 52,083,333 common shares, or 7.2% of its outstanding shares, at $192 apiece.

The aggregate cost of the purchase was about $10 billion.

Amgen said the tender offer was oversubscribed, and shares will be accepted on a pro rata basis. The proration factor for the tender offer is about 96.2%.

Bank of America Merrill Lynch and Morgan Stanley acted as dealer managers for the tender offer.